Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAmortization of Deferred ChargesAmortizatization of IntangiblesAmortizatization of IntangiblesCapital ExpendituresCapital ExpendituresCash from Financing ActivitiesCash from Financing ActivitiesCash from Investing ActivitiesCash from Investing ActivitiesCash from OperationsCash from OperationsChange in Account PayablesChange in Account PayablesChange in Accured ExpensesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in Acquisitions & DivestmentsChange in CashDepreciation & Amortization (CF)Depreciation & Amortization (CF)Free Cash FlowFree Cash FlowGains from Investment SecuritiesGains from Investment SecuritiesGains from Sales and DivestituresGains from Sales and DivestituresNet Cash FlowNet Cash FlowNet IncomeNon-cash ItemsNon-cash ItemsOther Working Capital ChangesOther Working Capital ChangesOther financing activitiesOther financing activitiesShare-based CompensationShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Cogent Biosciences (COGT) Gains from Investment Securities (2017 - 2026)

Cogent Biosciences' Gains from Investment Securities history spans 10 years, with the latest figure at $1.1 million for Q1 2026.

  • Quarterly Gains from Investment Securities fell 19.8% to $1.1 million in Q1 2026 from the year-ago period, while the trailing twelve-month figure was $1.1 million through Mar 2026, down 19.8% year-over-year, with the annual reading at $340000.0 for FY2025, 87.47% down from the prior year.
  • Gains from Investment Securities came in at $1.1 million for Q1 2026, up from $340000.0 in the prior quarter.
  • In the past five years, Gains from Investment Securities ranged from a high of $15.5 million in Q4 2023 to a low of -$24.2 million in Q4 2022.
  • The 5-year median for Gains from Investment Securities is $822997.5 (2022), against an average of $348463.4.
  • Year-over-year, Gains from Investment Securities tumbled 810.72% in 2022 and then surged 602.61% in 2025.
  • Cogent Biosciences' Gains from Investment Securities stood at -$24.2 million in 2022, then soared by 164.1% to $15.5 million in 2023, then crashed by 82.49% to $2.7 million in 2024, then tumbled by 87.47% to $340000.0 in 2025, then skyrocketed by 237.88% to $1.1 million in 2026.
  • Per Business Quant, the three most recent readings for COGT's Gains from Investment Securities are $1.1 million (Q1 2026), $340000.0 (Q4 2025), and $302733.0 (Q3 2025).